請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76943完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張雅貞(Ya-Jen Chang) | |
| dc.contributor.author | Yu-Tse Ting | en |
| dc.contributor.author | 丁宇澤 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:41:10Z | - |
| dc.date.available | 2021-07-10T21:41:10Z | - |
| dc.date.copyright | 2020-09-04 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-06 | |
| dc.identifier.citation | 1. Mims, J.W., Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol, 2015. 5 Suppl 1: p. S2-6. 2. Anandan, C., et al., Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy, 2010. 65(2): p. 152-167. 3. Mattiuzzi, C. and G. Lippi, Worldwide asthma epidemiology: insights from the Global Health Data Exchange database. International Forum of Allergy Rhinology, 2020. 10(1): p. 75-80. 4. Ying, Y., Y. Weng, and K. Chang, The Prevalence and Patient’s Quality of Life for Asthma in Taiwan. Int. J. Pul. Res. Sci, 2017. 1: p. 1-5. 5. Hsiao, H.J., et al., A nationwide survey of the severity, comorbidity, and mortality of hospitalized patients with asthma in Taiwan. Pediatr Neonatol, 2013. 54(4): p. 254-60. 6. Morahan, G., et al., Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. Lancet (London, England), 2002. 360(9331): p. 455-459. 7. Brusselle, G., et al., Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. American Journal of Respiratory Cell and Molecular Biology, 1995. 12(3): p. 254-259. 8. Kim, H.Y., et al., Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med, 2014. 20(1): p. 54-61. 9. Saglani, S., et al., IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol, 2013. 132(3): p. 676-685.e13. 10. Hargreave, F.E., J. Dolovich, and M.T. Newhouse, The assessment and treatment of asthma: A conference report. Journal of Allergy and Clinical Immunology, 1990. 85(6): p. 1098-1111. 11. Berger, W.E., Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs, 2005. 65(14): p. 1973-89. 12. Barisione, G., et al., Beta-Adrenergic Agonists. Pharmaceuticals (Basel), 2010. 3(4): p. 1016-1044. 13. Lambrecht, B.N. and H. Hammad, The immunology of asthma. Nature Immunology, 2015. 16(1): p. 45-56. 14. Kabata, H., et al., Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nature Communications, 2013. 4(1): p. 2675. 15. Cayrol, C. and J.P. Girard, Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev, 2018. 281(1): p. 154-168. 16. Cayrol, C. and J.-P. Girard, IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Current Opinion in Immunology, 2014. 31: p. 31-37. 17. Lingel, A., et al., Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure, 2009. 17(10): p. 1398-410. 18. Funakoshi-Tago, M., et al., TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cellular Signalling, 2008. 20(9): p. 1679-1686. 19. Miller, A.M., Role of IL-33 in inflammation and disease. Journal of Inflammation, 2011. 8(1): p. 22. 20. Chan, B.C.L., et al., IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Frontiers in immunology, 2019. 10: p. 364-364. 21. Sjöberg, L.C., et al., Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells. Allergy, 2015. 70(5): p. 514-521. 22. Lei, Y., et al., Insights into mast cell functions in asthma using mouse models. Pulm Pharmacol Ther, 2013. 26(5): p. 532-9. 23. McBrien, C.N. and A. Menzies-Gow, The Biology of Eosinophils and Their Role in Asthma. Frontiers in Medicine, 2017. 4: p. 93. 24. Foster, P.S., et al., Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. The Journal of experimental medicine, 1996. 183(1): p. 195-201. 25. Yamaguchi, Y., et al., Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med, 1988. 167(5): p. 1737-42. 26. Allakhverdi, Z., et al., CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol, 2009. 123(2): p. 472-8. 27. Liu, T., et al., Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respiratory Medicine, 2015. 109(11): p. 1391-1396. 28. Chen, R., et al., Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma. Am J Respir Crit Care Med, 2017. 196(6): p. 700-712. 29. Leckie, M.J., et al., Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. The Lancet, 2000. 356(9248): p. 2144-2148. 30. Foster, P.S., et al., Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med, 1996. 183(1): p. 195-201. 31. Spits, H., J.H. Bernink, and L. Lanier, NK cells and type 1 innate lymphoid cells: partners in host defense. Nature Immunology, 2016. 17(7): p. 758-764. 32. KleinJan, A., et al., Enforced expression of Gata3 in T cells and group 2 innate lymphoid cells increases susceptibility to allergic airway inflammation in mice. J Immunol, 2014. 192(4): p. 1385-94. 33. Bando, J.K. and M. Colonna, Innate lymphoid cell function in the context of adaptive immunity. Nature Immunology, 2016. 17(7): p. 783-789. 34. Holgate, S.T. and R. Polosa, Treatment strategies for allergy and asthma. Nat Rev Immunol, 2008. 8(3): p. 218-30. 35. Moro, K., et al., Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat Immunol, 2016. 17(1): p. 76-86. 36. Chang, Y.J., et al., Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol, 2011. 12(7): p. 631-8. 37. Bartemes, K.R., et al., IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol, 2012. 188(3): p. 1503-13. 38. Mjösberg, J., et al., The Transcription Factor GATA3 Is Essential for the Function of Human Type 2 Innate Lymphoid Cells. Immunity, 2012. 37(4): p. 649-659. 39. Mjösberg, J.M., et al., Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nature Immunology, 2011. 12(11): p. 1055-1062. 40. Jackson, D.J., et al., IL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations In Vivo. American Journal of Respiratory and Critical Care Medicine, 2014. 190(12): p. 1373-1382. 41. Kamekura, R., et al., The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clinical Experimental Allergy, 2012. 42(2): p. 218-228. 42. Bankova, L.G., et al., Maturation of mast cell progenitors to mucosal mast cells during allergic pulmonary inflammation in mice. Mucosal Immunology, 2015. 8(3): p. 596-606. 43. Galli, S.J. and M. Tsai, IgE and mast cells in allergic disease. Nature Medicine, 2012. 18(5): p. 693-704. 44. Xue, L., et al., Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol, 2014. 133(4): p. 1184-94. 45. Boyce, J.A., Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev, 2007. 217: p. 168-85. 46. Doherty, T.A., et al., Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. Journal of Allergy and Clinical Immunology, 2013. 132(1): p. 205-213. 47. Figueroa, D.J., et al., Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes. American Journal of Respiratory and Critical Care Medicine, 2001. 163(1): p. 226-233. 48. Laitinen, L.A., et al., Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet, 1993. 341(8851): p. 989-90. 49. Diamant, Z., et al., The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. American Journal of Respiratory and Critical Care Medicine, 1997. 155(4): p. 1247-1253. 50. Cole, J., et al., Chapter Four - The Role of Macrophages in the Innate Immune Response to Streptococcus pneumoniae and Staphylococcus aureus: Mechanisms and Contrasts, in Advances in Microbial Physiology, R.K. Poole, Editor. 2014, Academic Press. p. 125-202. 51. Gordon, S. and P.R. Taylor, Monocyte and macrophage heterogeneity. Nature Reviews Immunology, 2005. 5(12): p. 953-964. 52. Hume, D.A., Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunology, 2008. 1(6): p. 432-441. 53. Tao, X. and A. Xu, Chapter 2 - Basic Knowledge of Immunology, in Amphioxus Immunity, A. Xu, Editor. 2016, Academic Press. p. 15-42. 54. Gordon, S., Alternative activation of macrophages. Nat Rev Immunol, 2003. 3(1): p. 23-35. 55. Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012. 122(3): p. 787-95. 56. Murray, P.J., Macrophage Polarization. Annual Review of Physiology, 2017. 79(1): p. 541-566. 57. Chistiakov, D.A., et al., The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology, 2018. 223(1): p. 101-111. 58. Wolfs, I.M.J., M.M.P.C. Donners, and M.P.J. de Winther, Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost, 2011. 106(11): p. 763-771. 59. Raes, G., et al., Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol, 2002. 71(4): p. 597-602. 60. Stein, M., et al., Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med, 1992. 176(1): p. 287-92. 61. Moreira, A.P. and C.M. Hogaboam, Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interferon Cytokine Res, 2011. 31(6): p. 485-91. 62. Winkler, C., et al., Impact of endobronchial allergen provocation on macrophage phenotype in asthmatics. BMC immunology, 2014. 15: p. 12-12. 63. Lambrecht, B.N. and H. Hammad, The immunology of asthma. Nat Immunol, 2015. 16(1): p. 45-56. 64. Khanduja, K.L., et al., Corticosteroids affect nitric oxide generation, total free radicals production, and nitric oxide synthase activity in monocytes of asthmatic patients. Mol Cell Biochem, 2011. 346(1-2): p. 31-7. 65. Van der Auwera, I., et al., A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutrition Metabolism, 2005. 2(1): p. 28. 66. Sato, K., et al., Insulin, ketone bodies, and mitochondrial energy transduction. Faseb j, 1995. 9(8): p. 651-8. 67. DeVivo, D.C., et al., Chronic ketosis and cerebral metabolism. Ann Neurol, 1978. 3(4): p. 331-37. 68. Kennedy, A.R., et al., A high-fat, ketogenic diet induces a unique metabolic state in mice. American Journal of Physiology-Endocrinology and Metabolism, 2007. 292(6): p. E1724-E1739. 69. Vanitallie, T.B., et al., Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology, 2005. 64(4): p. 728-30. 70. Van der Auwera, I., et al., A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond), 2005. 2: p. 28. 71. Lemmon, M.E., et al., Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature. Dev Med Child Neurol, 2012. 54(5): p. 464-8. 72. Trevathan, E., Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol, 2002. 17 Suppl 2: p. 2s9-2s22. 73. Freeman, J.M., E.H. Kossoff, and A.L. Hartman, The ketogenic diet: one decade later. Pediatrics, 2007. 119(3): p. 535-43. 74. Stafstrom, C.E. and J.M. Rho, The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol, 2012. 3: p. 59. 75. Gibas, M.K. and K.J. Gibas, Induced and controlled dietary ketosis as a regulator of obesity and metabolic syndrome pathologies. Diabetes Metab Syndr, 2017. 11 Suppl 1: p. S385-s390. 76. Weber, D.D., S. Aminazdeh-Gohari, and B. Kofler, Ketogenic diet in cancer therapy. Aging (Albany NY), 2018. 10(2): p. 164-165. 77. Branco, A.F., et al., Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest, 2016. 46(3): p. 285-98. 78. Giordano, C., et al., Neuroactive Peptides as Putative Mediators of Antiepileptic Ketogenic Diets. Frontiers in Neurology, 2014. 5(63). 79. McDaniel, S.S., et al., The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia, 2011. 52(3): p. e7-11. 80. Ellenbroek, J.H., et al., Long-term ketogenic diet causes glucose intolerance and reduced β- and α-cell mass but no weight loss in mice. Am J Physiol Endocrinol Metab, 2014. 306(5): p. E552-8. 81. Kwiterovich, P.O., Jr., et al., Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. Jama, 2003. 290(7): p. 912-20. 82. Plecko, B., et al., Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr Res, 2002. 52(2): p. 301-6. 83. Newman, J.C. and E. Verdin, β-Hydroxybutyrate: A Signaling Metabolite. Annual Review of Nutrition, 2017. 37(1): p. 51-76. 84. Cahill, G.F., Jr., et al., Hormone-fuel interrelationships during fasting. J Clin Invest, 1966. 45(11): p. 1751-69. 85. Robinson, A.M. and D.H. Williamson, Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev, 1980. 60(1): p. 143-87. 86. Balasse, E.O. and F. Féry, Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev, 1989. 5(3): p. 247-70. 87. White, H. and B. Venkatesh, Clinical review: ketones and brain injury. Crit Care, 2011. 15(2): p. 219. 88. Singer, M., Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med, 2007. 35(9 Suppl): p. S441-8. 89. Yassen, K.A., et al., Mitochondrial redox state in the critically ill. Br J Anaesth, 1999. 83(2): p. 325-7. 90. Shimazu, T., et al., de CR, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science, 2013. 339: p. 211-214. 91. Kashiwaya, Y., et al., D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2000. 97(10): p. 5440-5444. 92. Tieu, K., et al., D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest, 2003. 112(6): p. 892-901. 93. Lim, S., et al., D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease. PLOS ONE, 2011. 6(9): p. e24620. 94. Kazantsev, A.G. and L.M. Thompson, Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews Drug Discovery, 2008. 7(10): p. 854-868. 95. Adcock, I.M., et al., Epigenetic regulation of airway inflammation. Current opinion in immunology, 2007. 19(6): p. 694-700. 96. Barnes, P.J., I.M. Adcock, and K. Ito, Histone acetylation and deacetylation: importance in inflammatory lung diseases. European Respiratory Journal, 2005. 25(3): p. 552. 97. Thio, C.L.-P., et al., Regulation of type 2 innate lymphoid cell–dependent airway hyperreactivity by butyrate. Journal of Allergy and Clinical Immunology, 2018. 142(6): p. 1867-1883.e12. 98. Lewis, G., et al., Dietary Fiber-Induced Microbial Short Chain Fatty Acids Suppress ILC2-Dependent Airway Inflammation. Frontiers in Immunology, 2019. 10: p. 2051. 99. Hartman, A.L. and J.M. Rho, The New Ketone Alphabet Soup: BHB, HCA, and HDAC. Epilepsy currents, 2014. 14(6): p. 355-357. 100. Bhavsar, P., T. Ahmad, and I.M. Adcock, The role of histone deacetylases in asthma and allergic diseases. Journal of Allergy and Clinical Immunology, 2008. 121(3): p. 580-584. 101. Balasse, E.O. and F. Féry, Ketone body production and disposal: Effects of fasting, diabetes, and exercise. Diabetes/Metabolism Reviews, 1989. 5(3): p. 247-270. 102. Otera, H., et al., Targeted inactivation of endothelial lipase attenuates lung allergic inflammation through raising plasma HDL level and inhibiting eosinophil infiltration. Am J Physiol Lung Cell Mol Physiol, 2009. 296(4): p. L594-602. 103. Glastras, S.J., et al., Mouse Models of Diabetes, Obesity and Related Kidney Disease. PLoS One, 2016. 11(8): p. e0162131. 104. Thio, C.L., et al., Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate. J Allergy Clin Immunol, 2018. 142(6): p. 1867-1883.e12. 105. Shimazu, T., et al., Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor. Science, 2013. 339(6116): p. 211. 106. Knight, P.A., et al., Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med, 2000. 192(12): p. 1849-56. 107. Pejler, G., The emerging role of mast cell proteases in asthma. European Respiratory Journal, 2019. 54(4): p. 1900685. 108. Yamauchi, K., [Regulation of gene expression of L-histidine decarboxylase and histamine N-methyl-transferase, and its relevance to the pathogenesis of bronchial asthma]. Nihon Rinsho, 1996. 54(2): p. 377-88. 109. Bai, C., et al., Association of 5-lipoxygenase gene polymorphisms with bronchial asthma. Experimental and therapeutic medicine, 2012. 4(6): p. 967-971. 110. Turner, J.-E., et al., IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. The Journal of experimental medicine, 2013. 210(13): p. 2951-2965. 111. Dong, W., et al., Attenuated allergic responses to house dust mite antigen in feed-restricted rats. Environmental health perspectives, 2000. 108(12): p. 1125-1131. 112. Underwood, D.C., et al., Food restriction-mediated adrenal influences on antigen-induced bronchoconstriction and airway eosinophil influx in the guinea pig. Int Arch Allergy Immunol, 1998. 117(1): p. 52-9. 113. Nakamura, S., et al., Fasting mitigates immediate hypersensitivity: a pivotal role of endogenous D-beta-hydroxybutyrate. Nutr Metab (Lond), 2014. 11: p. 40. 114. Everaere, L., et al., Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. J Allergy Clin Immunol, 2016. 138(5): p. 1309-1318.e11. 115. Robinette, M.L., et al., Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat Immunol, 2015. 16(3): p. 306-17. 116. Monticelli, L.A., et al., Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nature Immunology, 2016. 17(6): p. 656-665. 117. Molofsky, A.B., et al., Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med, 2013. 210(3): p. 535-49. 118. Karagiannis, F., et al., Lipid-Droplet Formation Drives Pathogenic Group 2 Innate Lymphoid Cells in Airway Inflammation. Immunity, 2020. 52(4): p. 620-634.e6. 119. Ho, L.H., et al., IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals. Journal of Leukocyte Biology, 2007. 82(6): p. 1481-1490. 120. Morita, H., et al., An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers. Immunity, 2015. 43(1): p. 175-186. 121. Hershko, Alon Y., et al., Mast Cell Interleukin-2 Production Contributes to Suppression of Chronic Allergic Dermatitis. Immunity, 2011. 35(4): p. 562-571. 122. Youm, Y.-H., et al., The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nature Medicine, 2015. 21(3): p. 263-269. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76943 | - |
| dc.description.abstract | β-羥基丁酸酯為一種由脂肪酸代謝而來的產物，也是在哺乳類動物當中最豐富的酮體，可以當作體內ATP生產的替代來源。在一般正常生理下，β-羥基丁酸酯的濃度非常低，然而在節食或是攝取生酮飲食的情況下，它的濃度能上升至2 mM。先前的研究指出在神經疾病的動物模式當中，β-羥基丁酸酯具有防止疾病惡化以及促進細胞再生的作用；也已經有研究證實提升血清中β-羥基丁酸酯的濃度可能有助於緩解過敏症狀，然而其中詳細的機制還有待更進一步的研究。因此本篇的研究目的主要是想探討β-羥基丁酸酯在過敏免疫反應當中所扮演的角色。在動物實驗中，我經由皮下包埋植入式滲透壓膠囊，長時間給予β-羥基丁酸酯並額外以腹腔注射提高體內的濃度後，在介白素-33所引起的肺部發炎小鼠模式當中，可以看到浸潤至肺部氣道腔室中的嗜酸性白血球數量有顯著的降低。根據細胞流式儀的實驗結果顯示，給予外源性β-羥基丁酸酯能夠抑制表現IL-5以及IL-13的第二型先天性淋巴細胞 (Group 2 Innate lymphoid cells; ILC2) 族群。接著，為了延長β-羥基丁酸酯的半衰期以及降低人為因素的干擾，我在小鼠飲水中給予β-羥基丁酸酯的前驅物1,3-丁二醇，之後再以鼻腔注射方式給予Alternaria alternata萃取物引發呼吸道過度反應，實驗結果也發現能夠有效地抑制真菌萃取物所引發的呼吸道發炎。接下來，我們透過給予小鼠生酮飼料來更真實模擬透過攝食來提升體內β-羥基丁酸酯濃度，並一樣以鼻腔注射方式給予Alternaria alternata萃取物引發過敏反應，結果發現生酮飼料能夠有效提升並維持血清中β-羥基丁酸酯濃度，也觀察到血清生理數值的變化，最重要的是能有效地降低真菌萃取物所引起第二型過敏反應。 基於以上小鼠疾病模式的結果，我們想進一步探討β-羥基丁酸酯對肺部ILC2細胞影響的機制，因此我們對小鼠肺部分選出的ILC2細胞給予β-羥基丁酸酯的處理，結果發現β-羥基丁酸酯並不會直接抑制經介白素-33處理的ILC2細胞分泌第二型細胞激素，而由於先前的研究指出β-羥基丁酸酯能降低肥大細胞的去顆粒作用(Mast cell degranulation)，因此我們給予經小鼠骨髓分化而來的細胞β-羥基丁酸酯的處理，結果發現能有效地抑制其產生第二型細胞激素以及介白素-2，並減少去顆粒化相關基因的表現。因此，我們推測β-羥基丁酸酯可能透過抑制肥大細胞產生的促發炎因子來進一步抑制ILC2分泌第二型細胞激素，實驗結果也證實細胞培養液中的第二型細胞素有明顯減少的趨勢。本篇研究證實，透過提升體內環境中β-羥基丁酸酯的濃度，能夠有效抑制由ILC2所引發的呼吸道發炎，並提供了攝取生酮飲食來提升體內β-羥基丁酸酯的濃度，或許能夠改善呼吸道過敏反應的方法，但β-羥基丁酸酯所介導的抑制效果並不直接作用於ILC2細胞上，而可能是透過抑制肥大細胞所產生的促發炎因子而造成的效果，但詳細的機制仍有待進一步的研究。 | zh_TW |
| dc.description.abstract | Beta-hydroxybutyrate (BHB) is one of the metabolites of fatty acids. In mammals, it is the most abundant ketone body and can serve as an alternative resource for adenosine triphosphate (ATP) production. In humans, the physiological concentration of BHB is typically in the low μM range. However, under fasting state or ketogenic diet (KD), the concentration of BHB can reach up 2 mM. It has been shown that BHB exerts protective function in neurological diseases in animal models. Also, previous studies have shown that elevation of serum BHB may alleviate hypersensitivity. However, the mechanism remains unclear. Thus, we would like to investigate the effect of BHB on the allergic immune response. Our data showed that giving BHB exogenously can inhibit IL-33-induced lung inflammation through suppressing Th2 cytokine production by ILC2s. Next, in order to give exogenous BHB through less manual intervention and solve short half-life of BHB, mice were administered with BHB precursor, 1,3-butanediol, through drinking water and treated with Alternaria alternata intranasally to induce airway hyperreactivity. The results indicated that elevation of serum BHB through drinking water can alleviate A. alternata-induced AHR and lung inflammation. In addition, we wondered whether elevation of BHB concentration through KD can alleviate Alternaria alternata-induced lung inflammation. Our results showed that administration of KD can elevate BHB concentration to 1 mM in the serum and alleviate airway hyperreactivity and inflammation. However, when we treated lung sorted ILC2s with BHB in vitro, the results showed that BHB did not inhibit cytokine production of ILC2s. Based on a study showed that BHB had suppressive effects on mast cell degranulation, so we wondered if BHB can also affect cytokine production of mast cells. Our data showed that a significant suppression on cytokine production of BM derived mast cells treated with BHB. Moreover, the gene expression of mast cell protease 1 (Mcpt1) and histidine decarboxylase (Hdc) were also decreased in mast cells treated with BHB. These data suggested that BHB had suppressive effects on mast cell activation. Finally, to investigate whether the suppressive effects of BHB on ILC2s in vivo are through interaction between mast cells and ILC2s, we co-cultured lung ILC2s with BM mast cells in the presence or absence of BHB. Our data showed that a significant reduction of Th2 cytokines, such as IL-5 and IL-13, from ILC2s was correlated with a great decreasing level of IL-2 and IL-9 from mast cells. This data indicated that BHB may inhibit Th2 cytokine production of ILC2s via decreasing IL-2 and IL-9 produced from mast cells. Overall, this study demonstrated that elevating the level of the ketone body, beta-hydroxybutyrate (BHB), in the circulatory system can alleviate ILC2-dependent airway inflammation and the suppressive effects of BHB may be through inhibiting mediators produced from mast cells to regulate effector functions of ILC2s. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:41:10Z (GMT). No. of bitstreams: 1 U0001-0508202013521000.pdf: 3127889 bytes, checksum: b0e20bb22cb7df43cb07a927273501a1 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | Introduction 1 Asthma 1 Interleukin-33 (IL-33) in asthma 2 The role of eosinophils in asthma 3 Group 2 innate lymphoid cells (ILC2s) 4 Mast cells 6 Macrophages 8 Ketogenic diet 9 Beta-hydroxybutyrate (BHB) 11 Histone Deacetylases (HDACs) 12 Specific aims 13 Materials and methods 14 Mice 14 Lung ILC2 sorting 14 In vitro ILC2 culture 15 In vitro culture of bone marrow-derived mast cells (BMMCs) 15 In vitro co-culture of ILC2s and bone marrow-derived mast cells (BMMCs) 15 Bronchoalveolar lavage fluid (BALF) collection 16 Lung processing and Cell suspension preparation 16 Intracellular cytokine staining 17 Osmotic minipump studies 18 Measurement of AHR 18 Β-Hydroxybutyrate colorimetric assay 18 RNA extraction and reverse transcription 19 Quantitative Real-time PCR 19 Western blot 19 Statistical analysis 20 Results 21 Systemic administration of BHB ameliorates ILC2-mediated lung inflammation 21 Administration of 1,3-butanediol through drinking water suppresses Alternaria alternata-induced AHR and lung inflammation in mice 21 Ketogenic diet elevates serum BHB level and does not affect body weight in mice 22 The effects of ketogenic diet on mouse blood biochemistry 23 Ketogenic diet suppresses Alternaria alternata-induced AHR and type 2 inflammation 24 BHB does not directly inhibit cytokine production of ILC2s in vitro 24 BHB does not have any effects on histone 3 acetylation in ILC2s 25 BHB can inhibit cytokine production of bone marrow derived mast cells 25 The suppressive effects of BHB on cytokine production of BMMCs may be through histone 3 acetylation 26 BHB can suppress expression of degranulation-related genes in BM-derived mast cells 27 Co-culturing ILC2s with BM-derived mast cells in the presence of IL-33 can induce synergistic effects on cytokine production 28 BHB suppresses cytokine production by ILC2s through inhibition of mast cell-derived mediators 28 Conclusion 30 Discussion 32 Future work 35 References 37 Figures 53 Appendix 78 | |
| dc.language.iso | en | |
| dc.subject | 第二型先天性淋巴細胞 | zh_TW |
| dc.subject | β-羥基丁酸酯 | zh_TW |
| dc.subject | 生酮飲食 | zh_TW |
| dc.subject | 過敏 | zh_TW |
| dc.subject | ILC2 | en |
| dc.subject | beta-hydroxybutyrate | en |
| dc.subject | allergy | en |
| dc.subject | Ketogenic diet | en |
| dc.title | β-羥基丁酸酯對過敏性免疫反應的影響 | zh_TW |
| dc.title | The effect of beta-hydroxybutyrate on the allergic immune responses | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃怡萱(Yi-Shuian Huang),徐志文(Jr-Wen Shui) | |
| dc.subject.keyword | β-羥基丁酸酯,過敏,第二型先天性淋巴細胞,生酮飲食, | zh_TW |
| dc.subject.keyword | beta-hydroxybutyrate,allergy,ILC2,Ketogenic diet, | en |
| dc.relation.page | 78 | |
| dc.identifier.doi | 10.6342/NTU202002458 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-08-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0508202013521000.pdf 未授權公開取用 | 3.05 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。